The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective

BACKGROUND: The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for neovascular age-related macular degeneration (AMD), albeit unregistered...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Main Authors: van Asten, Freekje, Michels, Charlotte T. J., Hoyng, Carel B., van der Wilt, Gert Jan, Klevering, B. Jeroen, Rovers, Maroeska M., Grutters, Janneke P. C.
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2018
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5957378/
https://ncbi.nlm.nih.gov/pubmed/29772018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0197670
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares